Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1949 5
1950 3
1951 6
1952 6
1953 8
1954 6
1955 7
1956 4
1957 7
1958 3
1959 4
1960 2
1961 8
1962 6
1963 4
1964 2
1975 10
1976 19
1977 17
1978 17
1979 23
1980 21
1981 38
1982 98
1983 78
1984 127
1985 192
1986 250
1987 271
1988 290
1989 431
1990 501
1991 572
1992 619
1993 713
1994 749
1995 809
1996 865
1997 853
1998 867
1999 870
2000 915
2001 935
2002 876
2003 822
2004 838
2005 862
2006 913
2007 865
2008 817
2009 804
2010 870
2011 879
2012 923
2013 863
2014 912
2015 937
2016 907
2017 859
2018 817
2019 829
2020 983
2021 979
2022 873
2023 61
Text availability
Article attribute
Article type
Publication date

Search Results

27,659 results
Results by year
Filters applied: . Clear all
Page 1
Etoposide: four decades of development of a topoisomerase II inhibitor.
Hande KR. Hande KR. Eur J Cancer. 1998 Sep;34(10):1514-21. doi: 10.1016/s0959-8049(98)00228-7. Eur J Cancer. 1998. PMID: 9893622 Review.
The history of the development of one of the first identified topoisomerase II inhibitors, etoposide, is reviewed in this paper. Critical developments in etoposide's mechanism of action, pharmacology and administration schedule are summarised. The clinical be …
The history of the development of one of the first identified topoisomerase II inhibitors, etoposide, is reviewed in this paper. Crit …
Etoposide pharmacology.
Hande KR. Hande KR. Semin Oncol. 1992 Dec;19(6 Suppl 13):3-9. Semin Oncol. 1992. PMID: 1492225 Review.
Etoposide's antineoplastic activity is achieved through DNA strand breakage, which likely results from the formation of a complex involving drug, DNA, and the DNA unwinding enzyme, topoisomerase II. ...A number of etoposide metabolites have been confirmed or
Etoposide's antineoplastic activity is achieved through DNA strand breakage, which likely results from the formation of a comp
Etoposide: an update.
Fleming RA, Miller AA, Stewart CF. Fleming RA, et al. Clin Pharm. 1989 Apr;8(4):274-93. Clin Pharm. 1989. PMID: 2653712 Review.
The disposition of etoposide in patients with renal and hepatic dysfunction is discussed. ...The impact of etoposide on prolonging survival in lung and testicular cancer is addressed, and studies evaluating the pharmacodynamics of etoposide are described. ...
The disposition of etoposide in patients with renal and hepatic dysfunction is discussed. ...The impact of etoposide on prolon …
Oral etoposide.
Phillips NC. Phillips NC. Drug Intell Clin Pharm. 1988 Nov;22(11):860-3. doi: 10.1177/106002808802201103. Drug Intell Clin Pharm. 1988. PMID: 3069425 Review.
Although no clinical trials comparing intravenous and oral etoposide in SCLC have been reported, several pharmacokinetic studies have been described. ...Other pharmacokinetic parameters are similar for both the intravenous and oral methods of administration. Based on these …
Although no clinical trials comparing intravenous and oral etoposide in SCLC have been reported, several pharmacokinetic studies have …
Etoposide (VP-16-213).
Issell BF, Crooke ST. Issell BF, et al. Cancer Treat Rev. 1979 Jun;6(2):107-24. doi: 10.1016/s0305-7372(79)80045-6. Cancer Treat Rev. 1979. PMID: 385138 Review. No abstract available.
Etoposide in leukemia.
Bishop JF, Lowethal R, Joshua D, Matthews JP, Wolf MM, Cooper IA. Bishop JF, et al. Cancer. 1991 Jan 1;67(1 Suppl):285-91. doi: 10.1002/1097-0142(19910101)67:1+<285::aid-cncr2820671313>3.0.co;2-2. Cancer. 1991. PMID: 1984829 Review.
Etoposide (VP16-213, NSC 141540) induces a complete response (CR) in 15% to 25% of previously treated patients with acute nonlymphocytic leukemia (ANLL) when used as a single agent. Etoposide has been used successfully in combination with cytarabine, daunorubicin, a
Etoposide (VP16-213, NSC 141540) induces a complete response (CR) in 15% to 25% of previously treated patients with acute nonlymphocy
Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death.
Woo SH, Kim B, Kim SH, Jung BC, Lee Y, Kim YS. Woo SH, et al. BMB Rep. 2022 Mar;55(3):148-153. doi: 10.5483/BMBRep.2022.55.3.119. BMB Rep. 2022. PMID: 34674796 Free PMC article.
We observed that co-treatment with etoposide and PEMFs led to a decrease in viable cells compared with cells solely treated with etoposide. PEMFs elevated the etoposide- induced PARP cleavage and caspase-7/9 activation and enhanced the etoposide-induce …
We observed that co-treatment with etoposide and PEMFs led to a decrease in viable cells compared with cells solely treated with e
Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature.
Pringle NR, Gilbar PJ, Grewal GD. Pringle NR, et al. J Oncol Pharm Pract. 2022 Jun;28(4):1019-1023. doi: 10.1177/10781552211073345. Epub 2022 Jan 17. J Oncol Pharm Pract. 2022. PMID: 35037804 Review.
INTRODUCTION: Hypersensitivity reactions from intravenous (IV) etoposide have been rarely reported, with these being seen more commonly with etoposide than with etoposide phosphate. ...Hypersensitivity reactions to etoposide phosphate are therefore lik …
INTRODUCTION: Hypersensitivity reactions from intravenous (IV) etoposide have been rarely reported, with these being seen more common …
Etoposide in gastric cancer.
Macdonald JS, Havlin KA. Macdonald JS, et al. Semin Oncol. 1992 Dec;19(6 Suppl 13):59-62. Semin Oncol. 1992. PMID: 1492227 Review.
Etoposide has modest single-agent activity (21% partial response rate) in patients with previously untreated metastatic gastric carcinoma. The use of etoposide in combination with agents like doxorubicin, cisplatin, and 5-fluorouracil with or without leucovorin has
Etoposide has modest single-agent activity (21% partial response rate) in patients with previously untreated metastatic gastric carci
Etoposide: twenty years later.
Hainsworth JD, Greco FA. Hainsworth JD, et al. Ann Oncol. 1995 Apr;6(4):325-41. doi: 10.1093/oxfordjournals.annonc.a059180. Ann Oncol. 1995. PMID: 7619747 Free article. Review.
Since the beginning of its clinical development 20 years ago, etoposide has become an important and widely used agent in clinical oncology. ...Exciting possibilities for the future include exploration of etoposide in combination with the topoisomerase I inhibitors, …
Since the beginning of its clinical development 20 years ago, etoposide has become an important and widely used agent in clinical onc …
27,659 results
You have reached the last available page of results. Please see the User Guide for more information.